Cannell & Spears LLC Has $88.79 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Cannell & Spears LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 3.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 664,473 shares of the life sciences company’s stock after purchasing an additional 24,716 shares during the quarter. Illumina comprises approximately 1.8% of Cannell & Spears LLC’s investment portfolio, making the stock its 7th biggest position. Cannell & Spears LLC’s holdings in Illumina were worth $88,794,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ILMN. Versant Capital Management Inc grew its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the fourth quarter worth $32,000. Assetmark Inc. boosted its position in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after acquiring an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina in the fourth quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. bought a new position in Illumina during the fourth quarter worth about $48,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 2.8 %

Shares of ILMN opened at $80.00 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 52 week low of $79.30 and a 52 week high of $156.66. The stock has a market capitalization of $12.67 billion, a price-to-earnings ratio of -10.42, a PEG ratio of 1.60 and a beta of 1.17. The stock has a fifty day moving average of $102.80 and a 200-day moving average of $126.82.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. Robert W. Baird dropped their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Canaccord Genuity Group cut their target price on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. Finally, TD Cowen cut Illumina from a “buy” rating to a “hold” rating and decreased their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.